SURUNKALI BUYRAK KASALLIGI BOʼLGAN BEMORLARD ANTIAGREGANT TERAPIYANI SAMARADORLIGINI O’RGANISH ORQALI DAVOLASHNI MUQOBILLASHTIRISH
Keywords:
surunkali buyrak kasalligi, alltrombosepinAbstract
Maqolada Surunkali buyrak kasalligi (SBK) III bosqichidagi68 ta bemorlarda antiagregant preperatlarning gemostaz sistemasiga ta’sir effektivligini qiyosiy baholash bo’yicha tadiqoqot natijalari taqdim etilgan. Bizning tadqiqotimiz shuni isbotladiki, mahalliy hom ashyolardan olindigan alltrombosepin preparati uzoq vaqt SBKlarini davolashda davomida keng qo’llanib kelayotgan antiagregant preparati atsetilsalitsil kislotadan qolishmaydi.
References
Rivera J, Navarro-Nunez L, Visente V: Trombotsitlar retseptorlari va tromb shakllanishi dinamikasida signalizatsiya. Haematologica 94 : 700–711, 2009 Stepanov YU.M., Kononov I.N., Jurbina A.I., Filippova A.YU. Arginin v meditsinskoy praktike.// Jurn. AMN Ukraїni -2013-№10(1)- str. 340–352.
Levy AS, Koresh J, El Nahas M, Astor BC, Matsushita K, va boshqalar: Surunkali buyrak kasalligining ta'rifi, tasnifi va prognozi: KDIGO bahslari konferentsiyasining hisoboti. Buyrak Int 80: 17–28, 2011
14. Levy AS, Beto JA, Eknoyan G, Foley RN, Kasiske BL. va boshqalar: Surunkali buyrak kasalligida yurak-qon tomir epidemiyasiga qarshi kurash: biz nimani bilamiz? Biz nimani o'rganishimiz kerak? Bu yerdan qayerga boramiz? Milliy buyrak fondi yurak-qon tomir kasalliklari bo'yicha ishchi guruhi. Am J Kidney Dis 32: 853–906,
Chju Z.B., Chjan R.Y., Chjan J.S., Xu J., Yang Z.Q. va boshqalar: O'rtacha va og'ir buyrak etishmovchiligi sirolimusni chiqaradigan stentlarning trombozi uchun xavf omilidir. RIFT tadqiqoti. Kardiologiya 112: 191–199, 2019
2022–2060, 2017
Guo AS, Chertow GM, McCulloch SE, Xu XY. Surunkali buyrak kasalligi va o'lim xavfi, yurak-qon tomir kasalliklari va kasalxonaga yotqizish. N. Ingliz tili J. Med. 2014; 351(13):1296–1305. doi: 10.1056/NEJMoa041031.Erratum.In:NEnglJMed.2008;18(4):4.
Baaten CCFMJ, Schröer JR, Floege J, Marx N, Jankowski J, Berger M, Noels H. Platelet Abnormalities in CKD and Their Implications for Antiplatelet Therapy. Clin J Am Soc Nephrol. 2022 Jan;17(1):155-170.. 2021
Su X, Yan B, Wang L, Lv J, Cheng H, Chen Y. Effect of antiplatelet therapy on cardiovascular and kidney outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. BMC Nephrol. 2019 Aug
Palmer SC, Di Micco L, Razavian M, Craig JC, Perkovic V, Pellegrini F, Jardine MJ, Webster AC, Zoungas S, Strippoli GF. Antiplatelet agents for chronic kidney disease. Cochrane Database Syst Rev. 2013 Feb
Floege J, Schlieper G. Chronic kidney disease: How effective and safe are antiplatelet agents in CKD? Nat Rev Nephrol. 2013 Jun;
